© 2026 NervNow™. All rights reserved.
ByNN Desk
Aidoc Just Raised $150M, Its IPO Plans Are Now in Focus
Aidoc has secured $150M in Series E funding led by Goldman Sachs, pushing its total raise past $500M as it accelerates its CARE clinical AI foundation model.
Aidoc has secured $150M in Series E funding led by Goldman Sachs, pushing its total raise past $500M as it accelerates its CARE clinical AI foundation model.
Clinical AI company Aidoc has raised $150 million in a Series E funding round, with Goldman Sachs Alternatives’ Growth Equity division leading the investment. The round, which closed April 29, 2026, also drew participation from General Catalyst, SoftBank Investment Advisors and NVentures, NVIDIA’s venture capital arm.
As a result of the raise, Aidoc’s total funding has now surpassed $500 million, less than a year after a separate $150 million growth round it closed in July 2025.
The pace of Aidoc’s fundraising reflects a rapidly maturing clinical AI sector. Indeed, the July 2025 round, which was led by General Catalyst and Square Peg with participation from four major U.S. health systems Hartford HealthCare, Mercy, Sutter Health and WellSpan Health had already pushed total funding to $370 million. The latest Series E, however, brings an entirely new cohort of institutional backers and marks a clear escalation in investor confidence.
Proceeds from the Series E will primarily support two strategic priorities. First, the company will further develop CARE its Clinical AI Reasoning Engine a foundation model that, unlike earlier AI tools focused on single conditions, can be adapted to perform a wide range of diagnostic tasks with minimal additional training. Second, Aidoc will drive broader global deployment of aiOS, its enterprise platform that allows hospitals to deploy, govern and integrate multiple AI solutions under one centralized operating framework.
Beyond that, Aidoc plans to build new capabilities such as automated imaging draft report creation, aimed at powering end-to-end clinical workflows from pixel analysis to preliminary reporting. The company says it intends to achieve this within two years.
Currently, Aidoc’s technology analyzes more than 60 million patient cases annually and is deployed across nearly 2,000 hospitals worldwide. The company holds 31 FDA clearances, spanning radiology, cardiology and neurology, the most in its category covering conditions ranging from intracranial hemorrhage and aortic dissection to incidental pulmonary embolism and rib fractures.
Furthermore, Aidoc recently received what it described as a landmark first FDA clearance for a comprehensive foundation model-based triage system in clinical imaging, a regulatory milestone that distinguishes it from most AI competitors still navigating the approval process.
The urgency behind Aidoc’s growth strategy, moreover, is grounded in a stark public health reality. Diagnostic errors and delays contribute to at least 400,000 deaths each year in the United States, according to figures cited by the company and corroborated by independent research. Rising imaging volumes, physician shortages and expanding clinical complexity have only widened that gap.
By 2030, every complex diagnostic decision should be supported by AI that enables earlier detection and reduces preventable error.
Elad Walach, Co-founder and CEO of Aidoc.
In addition to the funding milestone, Walach told Axios which first reported the Series E exclusively that Aidoc is targeting an initial public offering within three to five years. The company declined to disclose its current valuation or whether any existing investors sold shares in the round.
The raise comes, notably, amid intensifying competition in the radiology AI space. GE HealthCare completed a $2.3 billion acquisition of Intelerad in March 2026, while Siemens Healthineers has launched its own radiology services suite. RadAI, meanwhile, closed a $60 million Series C last month, valuing it at $525 million. Nevertheless, Aidoc’s regulatory depth, its installed base at nearly 2,000 hospitals and its transition toward a full foundation model architecture set it apart from most pure-play competitors.
Founded in Tel Aviv in 2016 and dually headquartered in Israel and New York, Aidoc builds clinical AI solutions that integrate directly into hospital workflows. Its aiOS platform supports both proprietary and third-party AI tools, with 69% of customers currently running non-Aidoc models on the platform, a figure that underscores its open ecosystem positioning.
Disclaimer: This news is based on publicly available information. NervNow has not independently verified any claims.
RECENT AI UPDATES
Circles and OpenAI Launch AI Concierge to Reshape Telecom Industry
Kleiner Perkins Leads Rogo’s $160M Series D for Finance AI Growth
Regular Users Could Detect AI Bias Before Deployment: New Research
Netweb Technologies Launches Tyrone ParallelStor Velox for AI, HPC Markets
Ctruh Raises $2.5 Million Fresh Funding to Scale Its 3D and AI Tools
